首页> 外文OA文献 >Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)

【2h】

Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)

机译：X-396（一种新型的间变性淋巴瘤激酶（ALK）抑制剂）在ALK +非小细胞肺癌（NSCLC）患者中的I / II期试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Reckamp Karen L.; Infante Jeffrey R.; Blumenschein George R.; Wakelee Heather; Carter Corey A.; Gockerman Jon P.; Lovly Christine; Dukart Gary; Harrow Kimberly; Liang Chris; Gibbons James J.; Horn Leora;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. P1.15-16 ALKConnect: An Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Patient Insights Network [J] . H. Lin, X. Pan, H. Huang, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第10期

机译：P1.15-16 Alkconnect：一种促进淋巴瘤激酶阳性（ALK +）非小细胞肺癌（NSCLC）患者见解网络
2. Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer [J] . Mohammad Jahanzeb, Huamao M. Lin, Xiaoyun Pan, The oncologist . 2020,第10期

机译：与Anploplastic淋巴瘤激酶（ALK）酪氨酸激酶抑制剂疗法的真实世界治疗模式和无进展生存期用于ALK +非小细胞肺癌
3. Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1 [J] . Kim D., Mehra R., Tan D. S. W., International Journal of Radiation Oncology, Biology, Physics . 2014,第5Suppla期

机译：Ceritinib在晚期间变性再生性淋巴瘤激酶（ALK）重排（ALK plus）非小细胞肺癌（NSCLC）患者中的疗效和安全性：ASCEND-1的更新
4. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Editorial on the article entitled brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial [O] . Ivana Sullivan, David Planchard 2016

机译：文章标题为 brigatinib在I / II期临床试验中对间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌患者的疗效和安全性的社论
7. EXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) [O] . L. Horn, Y.-L. Wu, M. Reck, 2017

机译：Extall3：Anaplastic淋巴瘤激酶（Alk）阳性非小细胞肺癌（NSCLC）中的肌氨基（X-396）的III期研究

Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)

著录项

引文网络

相似文献

相关主题

期刊订阅